Ordin nr. 1301/500/2008 din 11 iulie 2008 Partea a ii-a

eficient cu peniciline.

Infecţii severe cu germeni anaerobi.

Se aplică tuturor denumirilor comerciale, formelor farmaceutice şi concentraţiilor corespunzătoare DCI-ului.
________________________________________________________________________________

DCI/DENUMIRE COMERCIALĂ FORMA FARM.

__________________________________________________

CONCENTRAŢIE FIRMA

________________________________________________________________________________

J01FF01 CLINDAMYCINUM CAPS. 150 mg

DALACIN C 150 mg 150 mg PFIZER EUROPE MA EEIG
J01FF01 CLINDAMYCINUM CAPS. 300 mg

DALACIN C 300 mg 300 mg PFIZER EUROPE MA EEIG

________________________________________________________________________________
______________________________________________________________________________

| 297 |J01MA12| LEVOFLOXACINUM | |

|_______|_______|____________________________________________|_________________|
________________________________________________________________________________

DCI/DENUMIRE COMERCIALĂ FORMA FARM.

__________________________________________________

CONCENTRAŢIE FIRMA

________________________________________________________________________________

J01MA12 LEVOFLOXACINUM COMPR. FILM. 500 mg

TAVANIC(R) 500 mg AVENTIS PHARMA DEUTSCHLAND

GMBH

________________________________________________________________________________
______________________________________________________________________________

| 298 |J01MA14| MOXIFLOXACINUM | |

|_______|_______|____________________________________________|_________________|
________________________________________________________________________________

DCI/DENUMIRE COMERCIALĂ FORMA FARM.

__________________________________________________

CONCENTRAŢIE FIRMA

________________________________________________________________________________

J01MA14 MOXIFLOXACINUM COMPR. FILM. 400 mg

AVELOX(R) 400 mg 400 mg BAYER HEALTHCARE AG

________________________________________________________________________________

______________________________________________________________________________

| 299 |J02AC02| ITRACONAZOLUM* | |

|_______|_______|____________________________________________|_________________|
________________________________________________________________________________

DCI/DENUMIRE COMERCIALĂ FORMA FARM.

__________________________________________________

CONCENTRAŢIE FIRMA

________________________________________________________________________________

J02AC02 ITRACONAZOLUM CAPS. 100 mg

ITRACONAZOL 100 mg 100 mg TERAPIA S.A.

OMICRAL 100 mg 100 mg MEDICO UNO PHARMACEUTICAL

S.R.L

ORUNGAL 100 mg JANSSEN PHARMACEUTICA NV

________________________________________________________________________________
______________________________________________________________________________

| 300 |J05AB11| VALACYCLOVIRUM* | |

|_______|_______|____________________________________________|_________________|
________________________________________________________________________________

DCI/DENUMIRE COMERCIALĂ FORMA FARM.

__________________________________________________

CONCENTRAŢIE FIRMA

________________________________________________________________________________

J05AB11 VALACYCLOVIRUM COMPR. FILM. 500 mg

VALTREX 500 mg 500 mg THE WELLCOME FOUNDATION

LTD
Prescriere limitată: Tratamentul pacienţilor cu herpes zoster în decurs de 72 de ore de la debutul rash-ului

Prescriere limitată: Herpes zoster oftalmic.

Prescriere limitată: Herpes genital iniţial moderat/sever.

Prescriere limitată: Tratamentul episodic sau supresiv al herpesului genital recurent (forme moderate/severe).
________________________________________________________________________________
______________________________________________________________________________

| 301 |J05ABN1| BRIVUDINUM*# | |

|_______|_______|____________________________________________|_________________|
________________________________________________________________________________

DCI/DENUMIRE COMERCIALĂ FORMA FARM.

__________________________________________________

CONCENTRAŢIE FIRMA

________________________________________________________________________________
Prescriere limitată: Tratamentul pacienţilor cu herpes zoster în decurs de 72 de ore de la debutul rash-ului.
J05ABN1 BRIVUDINUM COMPR. 125 mg

BRIVAL(R) 125 mg BERLIN CHEMIE AG MENARINI

GROUP

________________________________________________________________________________

______________________________________________________________________________

| 302 |L01AA01| CYCLOPHOSPHAMIDUM* | |

|_______|_______|____________________________________________|_________________|
________________________________________________________________________________

DCI/DENUMIRE COMERCIALĂ FORMA FARM.

__________________________________________________

CONCENTRAŢIE FIRMA

________________________________________________________________________________

L01AA01 CYCLOPHOSPHAMIDUM DRAJ. 50 mg

ENDOXAN(R) 50 mg 50 mg BAXTER ONCOLOGY GMBH

________________________________________________________________________________

______________________________________________________________________________

| 305 |L02AE04| TRIPTORELINUM***# | Protocol: L013E |

|_______|_______|____________________________________________|_________________|
________________________________________________________________________________

DCI/DENUMIRE COMERCIALĂ FORMA FARM.

__________________________________________________

CONCENTRAŢIE FIRMA

________________________________________________________________________________
Prescriere limitată: Tratamentul de scurtă durată (până la 6 luni) al